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Illicit drugs are a global health problem, since both their acute and chronic consumption
have negative impacts on the drug user’s health. Drug checking facilities are receiving
growing interest as they allow drug users to chemically analyze their product prior to
consumption to assess the presence of adulterants or other non-expected substances.
Such harm reduction programs allow the reduction of the risks associated with drug
consumption without encouraging it. In particular, the emergence of new psychoactive
substances (NPS) emphasizes the risk for the population increasing the diversity and the
lability of illicit drugs on the market. Analytical developments are required to catch up
with this rapid evolution and reduce the potential harm caused by such consumption.
In this study, we developed a matrix-assisted laser desorption/ionization (MALDI)
high-resolution mass spectrometry (HRMS) strategy for the high-throughput qualitative
and quantitative analysis of drug checking samples. The use of online-based m/z
cloud library for untargeted compound search improved the ability to identify unknown
compounds. Sixty-seven drug checking samples were analyzed using this analytical
strategy, allowing the detection of 10 designer drugs and several classical drugs of
abuse (mainly cocaine and MDMA) as well as adulterants and contaminants. The results
were then compared with routine analyses of the same samples using conventional
approaches showing similar performance while removing the use of chromatographic
separation thus resulting in a significant reduction of the time required for sample
preparation and analysis. This study enlightens the potential of MALDI-HRMS as a
high-throughput approach allowing to speed-up up to six times the identification and
quantification of substances enabling to catch the fast changes on the drug of abuse
market. This strategy could be an interesting alternative analytical approach, allowing
better prevention and harm reduction for drug users.
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INTRODUCTION
The use of recreational drugs is widespread worldwide, and both the number of users and the
diversity of substances are increasing. In Europe, for instance, almost 25% of adults reported at
least one illicit drug consumption in their life (Liakoni et al., 2018). In Australia, the situation is
more concerning, indeed, in 2016, more than 40% of the population over 14 years old reported a
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drug use during their lifetimes and more than 15% during the
month preceding the survey (Day et al., 2018). Illicit drugs are
a global public health issue, since both their acute and chronic
consumption have pernicious impacts on the consumer’s health
(Crowley et al., 2017; Joye et al., 2017; Vearrier, 2019). For
instance, it is estimated that almost 10,000 overdose deaths
occurred in Europe in 2017 (EMCDDA, 2019).
The risk associated with drug consumption has also increased
with the emergence of new psychoactive substances (NPS)
or designer drugs leading to a significantly growing number
of emergency admissions and fatal overdoses (Miliano et al.,
2016). NPS are a rapidly evolving class of substances with
various physico-chemical properties and toxicological effects.
This class of molecules can be defined as all the substances that
are not controlled by the United Nations Single Convention
on Narcotic Drugs or the United Nations Convention on
Psychotropic substances but might pose public health issues
and are often “classical” drugs of abuse derivatives (Khaled
et al., 2016). Between 2012 and 2017, more than 400 NPS
were monitored for the first time (Elliott et al., 2018). The
risk with those substances is that only limited information is
available regarding their toxicity for both the drug user and the
healthcare professionals (Wood et al., 2016). Various analytical
procedures have been published for NPS monitoring in classical
and alternative matrices, especially regarding new synthetic
opioids (Pichini et al., 2017; Zawilska, 2017; Marchei et al.,
2018). For instance, screening procedures targeting a wide range
of NPS and designer stimulants as well as studies focusing on
designer benzodiazepines have been reported (Adamowicz and
Tokarczyk, 2016, 2019; Zawilska and Wojcieszak, 2019). The
development of those procedures alongside with the sharing
of information through early warning systems is capital to
reduce the risk of intoxications and fatalities associated with
NPS consumption.
Various drug checking facilities have emerged in the past 20
years. Those facilities allow the drug users to chemically analyze
their drugs to check for the presence of adulterants or other non-
expected substances without encouraging drug consumption
(Sande and Sabic, 2018). Such harm reduction programs provide
several advantages such as gaining contact with hard-to-reach
target group to provide information and counsel for an increased
prevention (Hungerbuehler et al., 2011). The analysis of those
substances also provides information regarding the prevalence
of drug consumption including NPS arriving on the market and
allows the monitoring of a potential altered substance presenting
risks. Indeed, evidence also suggests the potential synergistic
effect of certain toxic adulterants associated with the illicit drugs
leading to overdoses, severe health consequences, and even
deaths (Solimini et al., 2017; Singh et al., 2020).
On an analytical point of view, the continuous emergence
of new drugs presents an ongoing challenge for clinical
and forensic toxicology. Neither the serious toxicity or
impairment caused by such substances, nor the analytical
methods for their detection and identification is well-
established (Peters and Martinez-Ramirez, 2010). To adapt
to this constant apparition of new substances and the importance
of controlling the substances consumed by drug users, it
is necessary to develop analytical tools enabling fast and
reliable screening.
Among those analytical approaches, matrix-assisted laser
desorption/ionization (MALDI) allows a quick and simple
sample preparation. A wide range of use of MALDI technology
has been reported for drug monitoring. For instance, MALDI
ionization has been used for drug analysis in hair (Vogliardi
et al., 2010; Porta et al., 2011; Flinders et al., 2017) and
drug mapping in organs or whole-body tissue sections for
pharmacodynamic or toxicodynamic studies (Lietz et al., 2013;
Sun and Walch, 2013; Patel et al., 2015). Interestingly, an
Austrian research group reported the successful use of MALDI
combined with high-resolution (HR) MS for the qualitative
analysis on drug checking samples focusing on designer drugs
(Ostermann et al., 2014). Indeed, the introduction of HRMS
analyzers and especially Orbitrap technology increases mass
accuracy, allowing the facilitation of identification by reducing
the number of possible chemical formulas (Jagerdeo and Schaff,
2016; Joye et al., 2020). Moreover, by improving the mass
resolution power, HRMS increases the selectivity, therefore
reducing the potential interferences (Chindarkar et al., 2014).
Therefore, MALDI-HRMS technology seems to be an interesting
alternative to classical GC and LC-MS/MS analyses providing
a fast high-throughput complementary approach with a high
identification power.
The present study was performed in collaboration with the
association “Nuit Blanche” whose goal is to limit the risks
associated with drug consumption in the nightlife context of
the Swiss Canton of Geneva. This association collects drug
checking samples on a weekly basis that are routinely analyzed
by GC-MS regarding the screening approach and by LC-MS
for the quantitative analyses focusing on 12 substances. Herein,
we present a MALDI-HRMS procedure allowing the high-
throughput identification of a wide range of drugs of abuse
present in drug checking samples based on the online m/z cloud
library for untargeted compound search.
The method was applied to 67 real drug checking cases
revealing several NPS among the analyzed samples, as well
as adulterants. Globally, the method resulted in similar
performances than the conventional routine analyses with a
significant reduction of the analysis time. In the meantime, the
samples were quantified for the most detected drugs of abuse
using a single and simple sample preparation. To demonstrate
the potential of MALDI quantification in the context of drug
checking samples, we further performed a validation according to
the FDA (Food and Drug Administration) guidelines. The results
of this high-throughput qualitative and quantitative approach
were then compared with the classical methodology used in
routine showing similar results.
METHODS
Standard and Reagents
Drug checking samples were provided by the harm reduction
association “Nuit Blanche.” LSD, methamphetamine, MDEA,
MDMA, amphetamine, mephedrone, and cocaine, as well as
their deuterated analogs, were purchased as standards at 1
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FIGURE 1 | Analytical workflow of the MALDI qual/quant approach including two quick and simple sample preparations.
mg/ml either from Cerilliant or Lipomed. Acetonitrile (ULC-
MS 99.99%), methanol (ULC-MS 99.99%), water (ULC-MS),
formic acid 99% (ULC-MS), trifluoroacetic acid, as well as
the ammonium formate salt were purchased from Biolsolve.
Alpha-Cyano-4-hydroxycinnamic acid (CHCA) was purchased
from Sigma-Aldrich.
Sample Preparation
Regarding MALDI experiments, all samples were prepared
at 1 mg/ml and 100µg/ml for qualitative and quantitative
analyses, respectively. For qualitative analysis, 10 µl of the
sample solution was mixed with 10 µl of matrix solution
(CHCA 1 mg/ml, 1:1 ACN: H2O + 0.1% TFA). Concerning
quantitative analyses, 5 µl of sample solution was first mixed
with 5 µl of internal standard (IS) solution. Ten microliters of
matrix solution was then added to the mix. The IS solution
was prepared containing deuterated LSD, methamphetamine,
MDEA, MDMA, amphetamine, mephedrone, and cocaine at
10µg/ml. Calibration samples were prepared by spiking MeOH
at five concentration levels (six considering a blank) ranging from
0.1 to 50µg/ml with the same undeuterated substances than in
the IS solution; 1.5µl of sample/matrix solution was then spotted
on a MALDI stainless steel samples plate for analysis.
An experiment was conducted in order to evaluate the
minimal number of acquire spectra to minimize the variability
and, therefore, perform accurate quantification. Five samples
were prepared using MDMA at 10µg/ml with a 1:1 drug-to-IS
ratio. Five replicates were used to determine intra-spot variability
and the relative standard deviation of the signal at 1, 10, 20, 50,
100, and 150 laser shots, respectively.
Routine analyses were performed using two different sample
preparations including simple dilutions at 100µg/ml and
200 ng/ml and a derivation step. Regarding GC-MS screening
analyses, a first injection was performed with the diluted samples
at 100µg/ml. For the second injection, 100 µl of the 100µg/ml
sample solution was mixed with 100 µl of anhydric acetic
acid and 100 µl of pyridine for derivation. After vortexing,
the samples were incubated at 60◦C for 30min. Samples were
then evaporated and reconstituted in 100 µl of MeOH. For the
quantitative analyses, the dilution at 200 ng/ml was performed
in a 50/50 mix of formate buffer 5mM at pH 3 and MeOH
containing IS at a final concentration of 10 ng/ml. Calibration
samples were prepared by spiking MeOH at five concentration
levels ranging from 1 to 500 ng/ml.
MALDI Analyses
All samples were analyzed in a three-step process (Figure 1).
A first targeted approach targeting the most common drugs of
abuse and adulterant was processed, followed by a non-targeted
data-dependent acquisition for the detection and identification
of other drugs, adulterants, or dangerous contaminants. Then, a
full-scan experiment was operated for quantitative analysis.
All MALDI-HRMS experiments were performed using a
MALDI-LTQ-Orbitrap XL equipped with a 337-nm N2 laser
operating at 60Hz (Thermo Scientific, Bremen, Germany) with
a laser beam size of 60 × 50µm. All analyses were performed
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FIGURE 2 | Full scan data-dependent acquisition (DDA) based on the peaks’ intensity as an untargeted MALDI screening approach. The total ion current of all
acquisition (A), the full-scan spectra (B) and a fragmentation spectra comparison of 2C-B (C) are represented. In panel C, the top part represents the acquired
spectra while the bottom part is the reference spectra.
with a spectral resolution of 60,000 for full-scan experiments
and 17,500 regarding fragmentation. Both the automatic spectral
filtering (ASF) and the automatic gain control (AGC) were
switched off.MALDI plate motion was set to survey CPS.MALDI
laser energy was set to 5 µJ and the number of laser shot was
set to five in positive polarity. The scan masses were ranging
from 100 to 1,000 m/z.
Regarding qualitative analyses, first, a full-scan data-
dependant MS/MS approach was performed using an inclusion
list of 41 substances containing the most frequent drugs of abuse
and adulterants (Table S1). Fragmentation experiments were
performed using higher-energy collisional dissociation (HCD)
with normalized collision energy set between 30 and 100 eV
depending on the compounds of interest. The second full-scan
data-dependent approach was then performed for the detection
of other drugs, adulterants or contaminants using a non-targeted
approach (Figure 2). Based on the full-scan spectra, the 10 most
intense ions were then fragmented using HCD with a normalized
energy of 50 eV. A minimum signal threshold was set to 10,000
to avoid fragmenting noise. All fragmented compounds were
then sent to an exclusion list already containing the targeted
substances for 3min to avoid fragmenting always the same
substances. Quantitative analyses were performed averaging
120 acquired full-scan spectra. The validation criteria used to
evaluate the analytical process was based on the directives of
the FDA regarding bioanalytical methods and adapted to our
specific requirements. The validation was performed over three
non-consecutive days (p = 3). The trueness and precision were
evaluated using a variance analysis-based statistical treatment
(ANOVA). Calibration (Cal) was performed in duplicate at five
different concentration levels (k = 5) (Table 1) while quality
controls (QCs) were prepared in quadruplicate at the two lowest
and highest concentration levels (k= 4). Using the acquired data,
trueness, precision, accuracy, and linearity were determined.
Routine Analyses
GC screening analyses were performed using an existing
published procedure on a similar instrument (Lefrancois et al.,
2016). For the LC-MS/MS quantitative analyses, a Dionex
UltiMate 3000 LC-system (Thermo Fischer Scientific, Germany)
was used. Gradient elution was performed on a Chromolith
Performance RP-C18 (100 × 3mm) column using a 5mM
formate ammonium buffer at pH 3 (mobile phase A) and
acetonitrile (mobile phase B). The gradient and flow rate were
programmed as follows: 0–0.2min hold at 2% B; 0.2–8min
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TABLE 1 | Results for trueness, precision, and linearity (k is the number of
concentration levels, n the number of repetitions by levels, and p is the number of
non-consecutive days).
Trueness (%) (k = 4; n = 4; p = 3)
Calibration level (ng/ml) 100 1,000 10,000 50,000
MDMA 102.7 103.3 109.0 100.7
Cocaine 97.3 103.9 114.4 99.6
Repeatability/Intermediate precision (RSD%) (k = 4, n = 4, p = 3)
Calibration level (ng/ml) 100 1,000 10,000 50,000
MDMA 11.6/11.1 13.0/12.3 9.3/10.5 7.0/7.6
Cocaine 12.2/13.7 10.2/11.6 5.9/7.6 4.3/3.9
Linearity (k = 4, n = 4, p = 3)
Range (ng/ml) Slope R2 Exact mass (m/z)
MDMA 100–50,000 1.0037 0.9913 194.1176
Cocaine 100–50,000 0.9909 0.9966 304.1543
linear increase to 70% B; 8–10min linear increase to 95% of B;
10–11min hold at 95% B; 11–14min hold at 2% B at a constant
flow rate of 0.6 ml/min. The injection volume was set to 1 µl.
The LC system was coupled with a QTRAP 5500MS instrument
(SCIEX, Netherlands). The mass spectrometer was operated with
positive electrospray ionization in multiple reaction monitoring
(MRM) mode. The ion spray voltage was set to 5,500V and
the source temperature was 500◦C. The gas settings were as
follows: Curtain gas: 20 psi, ion source gas 1: 60 psi, ion source
gas 2: 40 psi.
Data Analysis
Information regarding the suspected sample’s composition was
almost always provided by the drug user. Then, MALDI data
were analyzed using Tracefinder (Thermo Scientific) and a
database created for this specific drug checking application.
Identification was based on the mass over charge ratio, the
isotopic pattern, and the library search based on MS/MS spectra
comparison. Regarding the samples containing a substance that
was not indexed in the library, Xcalibur was used combined with
different external library search such as Metlin or m/z cloud. The
data were analyzed using MSD Enhanced ChemStation (Agilent
Technologies) and compound characterization was performed
using mass spectra computerized databases, such as NIST
Version 2014 (National Institute of Standards and Technology),
Wiley Edition 10, MPW Version 2011 (Maurer, Pfleger, Weber,
Drugs, Poisons, Pesticides, Pollutants, and Metabolites), DD
Version 2014 (Drug Design and Discovery) and custom
databases from the University Institutes of Legal Medicine of the
Faculty of Medicine of Geneva (CURML). Quantitative results
were treated using Analyst software version 1.6.2.
RESULTS AND DISCUSSION
MALDI Qualitative Analyses
Consumption of drugs of abuse is a global public health issue.
In particular, the emergence of NPS including the classes of
phenethylamine and tryptamine emphasizes the risk for the
population. Therefore, the development of new fast screening
procedures allowing the identification of known and unknown
drugs of abuse is a priority to keep up with the ongoing
developments on the illicit drug market. The association of
highly concentrated analytes with the increased selectivity
brought by HRMS technology allows the facilitation of high-
throughput MALDI detection and identification of various
unknown substances.
With the developed MALDI-HRMS method, several
designer drugs were successfully identified including
2,5-dimethoxy-4-methylamphetamine (DOM), 2,5-
dimethoxy-4-bromoamphetamine (DOB), 2,5-dimethoxy-
4-chloroamphetamine (DOC), 2,5-dimethoxy-4-
bromophenethylamine (2C-B) and its position isomer
2-Br-4,5-DMPEA, 2,5-dimethoxy-4-ethylphenethylamine (2C-
E), methoxetamine, 4-hydroxy-N-methy-N-ethyltryptamine
(4-HO-MET), 6-(2-aminopropyl)benzofuran (6-APB), and
clephedrone. Moreover, the MALDI analysis allowed the
identification of various adulterants, contaminations, impurities,
and synthesis precursors such as safrole, which is used for the
synthesis of MDMA.
In total, 67 drug checking samples were analyzed with the
developed procedure leading to 101 identifications including
36 different substances (Table S2). Despite the identification
of several designer drugs, most samples contained classical
drugs of abuse, with 22 samples positive to cocaine and
16 samples positive to MDMA. All the active principles
detected using both approaches are represented in Figure 3A.
On average, the cocaine purity detected in the 22 samples
was high (71%), among them, 10 were containing levamisole,
while 9 of them were not containing any cutting agents
(Figure 3B). Only classical cocaine cutting agents were identified,
yet the identification of such substances is of importance since
evidence suggests the concomitant role of certain adulterants
and illicit drugs on toxicity (Solimini et al., 2017). The
GC-MS screening approach, which is the gold standard
for qualitative analyses, showed similar performances to the
developed MALDI procedure. Indeed, only one active principle
(GHB) was not detected using MALDI-HRMS. Among the
cutting agents, metabolites, precursors and alkaloids, one cocaine
metabolite (tropacocaine in two samples), and one adulterant
(phenacetine) were not detected by the developed approach.
On the other hand, one active principle (clephedrone), one
cocaine adulterant (levamisole in two samples), one cocaine
alkaloid (cinnamoylcocaine), and oneMDMAprecursor (safrole)
were not detected by the GC-MS approach (Figure 3). With
a coverage of 98.5% regarding the active principles and 91%
considering all the substances (see Figures 4A,B), the main
difference between those two approaches was that the use of
MALDI analyses allowed the reduction of the time spent for the
sample preparation with the removal of the derivation process
and the analysis by a six times factor reaching a total analysis
times of around 10min per sample.
MALDI Quantitative Analyses
MALDI analyses are often associated with a relatively important
variability regarding signal intensity. Therefore, MALDI
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FIGURE 3 | Active principles (A) and cocaine cutting agents (B) repartition among 67 drug checking samples. Twenty-two cocaine samples were analyzed with an
average purity of 71%.
FIGURE 4 | Performance comparison of the developed MALDI qual/quant approach with the routine analyses. Qualitative comparison for actives principles (A) and
considering all substances (B), as well as quantitative analyses for cocaine (C) and MDMA (D) are represented.
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FIGURE 5 | Relative standard deviation (%) associated with MALDI analysis as a function of the number of averaged acquisition points (A). Intra-spot variability and
accuracy depending on the number of laser shot averaged per acquisition (B).
FIGURE 6 | Accuracy profile for cocaine (A), and MDMA (B).
quantification requires specific development to ensure good
results in terms of accuracy, precision, and repeatability (Porta
et al., 2015). One solution to limit this specific signal variability
issue is to normalize the intensity obtained by averaging
enough acquired pixels. One of the challenges is to find the
right compromise between the time of acquisition associated
with the number of averaged spectra and a good accuracy
and precision. During this study, tests were performed to
optimize the acquisition time with a limited variability. As
demonstrated in the literature, our results enlightened the
need for isotopically labeled IS and acquisition of a sufficient
number of spectra to decrease relative standard deviation below
10% (Figure 5) (Ostermann et al., 2014; Porta et al., 2015). As
demonstrated in Figure 5, the acquisition of more than 100
averaged spectra was thus necessary to obtain good repeatability
and accuracy.
The validation of the quantitative approach was performed for
cocaine and MDMA by analyzing independent QC samples in
quadruplicates at four different calibration levels over three non-
consecutive days for the determination of trueness, precision,
and linearity. Accuracy represents the total error and can
be divided into two parameters including trueness (bias or
systematic error) and precision (the standard deviation or
random errors). Trueness is calculated using the percentage
difference between the experimental and the expected values.
In the present study, trueness was ranging from −2.7 to
14.4% (Table 1). Precision was divided into repeatability and
the inter-day variability (intermediate precision). Repeatability
represents the variability under similar conditions performed by
the same operator while intermediate precision is the variability
associated with the use of the same samples on different
days with different reagents. Repeatability and intermediate
precision were measured between 3.9 and 13.7% (Table 1).
Accuracy profiles are visual representations of the uncertainty
measurement combining the trueness and precision (Figure 6).
Precision is represented by the calculated confidence limit at
95% for each concentration limit. Accuracy profiles also include
the representation of acceptance limits of ±30% suggested for
method validation. Linearity is defined as the method capacity to
provide a result proportional to the real sample concentration. Its
determination requires linear regressionmodel based on the least
square method applied on the fit of the obtained concentrations
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as a function of the expected concentrations. Slope values were
calculated at 1.0037 and 0.9909 with coefficients of determination
of 0.9913 and 0.9966 for MDMA and cocaine, respectively.
Overall, MALDI quantitative results showed a good
correlation with the routine LC-MS/MS MRM experiments.
Indeed, all MALDI results were in agreement with the routine
analysis with a ±20% tolerance window. The correlation
between the two analytical strategies is represented in Figure 4
for cocaine and MDMA, being the two most detected substances.
Interestingly, among all MDMA-positive cases, two groups
can be distinguished. Indeed, all the samples in the form of
pills had an MDMA percentage between 31 and 52%, while
this percentage was measured between 78 and 84% regarding
powders (Figure 4D). MALDI quantitation analyses were
performed in around 3min per sample while one LC injection
lasted for 14min. With the HRMS quantification being based
on full-scan spectra, the addition of new substances of interest
can easily be performed without the need of any preliminary
developments such as infusion processes.
CONCLUSION
In this study, we enlighten the potential of MALDI-HRMS as
a high-throughput analytical strategy in forensic and clinical
toxicology. This technology can bring interesting applications
despite the absence of chromatographic separation, which may
be detrimental for the analysis of low-concentration analytes
in complex matrices. Nevertheless, considering drug checking
analysis where the analytes can be concentrated at will, MALDI-
HRMS allows one to significantly speed up the detection,
identification, and quantification of various drugs of abuse.
With the development of bioinformatic tools and online shared
libraries such as m/z cloud, the method can easily be adapted for
any new substance appearing on the market being in agreement
with the challenges brought by the continuous emergence of NPS.
The developed approach showed similar qualitative and
quantitative results for drug checking compared to those
obtained from both LC-MS and GC-MS while reducing by
six times the analytical procedure. The development of such
rapid drug checking strategies would enable faster monitoring
of changes in the drug market, providing an improved tool for
prevention and harm reduction for drug users.
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